Format
Sort by
Items per page

Send to

Choose Destination

Best matches for antagonists AND mortality vital statistics AND septicemia AND systemic infection:

Thymic stromal lymphopoietin mediates the host response and increases mortality during sepsis. Kuethe JW et al. J Surg Res. (2014)

Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. Sardinha J et al. Mediators Inflamm. (2014)

Use of antiplatelet agents in sepsis: a glimpse into the future. Akinosoglou K et al. Thromb Res. (2014)

Search results

Items: 1 to 20 of 1103

1.

Mechanisms of action of intravenous immunoglobulin in septic encephalopathy.

Esen F, Ozcan PE, Tuzun E, Boone MD.

Rev Neurosci. 2017 Dec 12. pii: /j/revneuro.ahead-of-print/revneuro-2017-0065/revneuro-2017-0065.xml. doi: 10.1515/revneuro-2017-0065. [Epub ahead of print]

PMID:
29232196
2.

Early antagonism of cerebral high mobility group box-1 protein is benefit for sepsis induced brain injury.

Ren C, Tong YL, Li JC, Dong N, Hao JW, Zhang QH, Yao YM.

Oncotarget. 2017 Oct 5;8(54):92578-92588. doi: 10.18632/oncotarget.21502. eCollection 2017 Nov 3.

3.

Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days.

Fuchs C, Wauschkuhn S, Scheer C, Vollmer M, Meissner K, Kuhn SO, Hahnenkamp K, Morelli A, Gründling M, Rehberg S.

Br J Anaesth. 2017 Oct 1;119(4):616-625. doi: 10.1093/bja/aex231.

PMID:
29121280
4.

Preoperative aldosterone receptor blockade and outcomes of cardiac surgery in patients with chronic kidney disease
.

Shavit L, Silberman S, Tauber R, Merin O, Bitran D, Fink D.

Clin Nephrol. 2017 Oct 26. doi: 10.5414/CN109236. [Epub ahead of print]

PMID:
29092740
5.

Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors.

Erwin BL, Denaburg MA, Barker AB, McArdle PJ, Windham ST, Morgan CJ.

Crit Care Med. 2017 Dec;45(12):e1226-e1232. doi: 10.1097/CCM.0000000000002729.

PMID:
28991825
6.

Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

Esatoglu SN, Hatemi G, Ugurlu S, Gokturk A, Tascilar K, Ozdogan H.

Medicine (Baltimore). 2017 Aug;96(34):e7859. doi: 10.1097/MD.0000000000007859.

7.

Sulforaphane Reduces HMGB1-Mediated Septic Responses and Improves Survival Rate in Septic Mice.

Lee IC, Kim DY, Bae JS.

Am J Chin Med. 2017;45(6):1253-1271. doi: 10.1142/S0192415X17500690. Epub 2017 Aug 22.

PMID:
28830206
8.

Cytosolic Phospholipase A<sub>2</sub>α Promotes Pulmonary Inflammation and Systemic Disease during Streptococcus pneumoniae Infection.

Bhowmick R, Clark S, Bonventre JV, Leong JM, McCormick BA.

Infect Immun. 2017 Oct 18;85(11). pii: e00280-17. doi: 10.1128/IAI.00280-17. Print 2017 Nov.

PMID:
28808157
9.

IL-33 Attenuates Sepsis by Inhibiting IL-17 Receptor Signaling through Upregulation of SOCS3.

Lv R, Zhao J, Lei M, Xiao D, Yu Y, Xie J.

Cell Physiol Biochem. 2017;42(5):1961-1972. doi: 10.1159/000479836. Epub 2017 Aug 9.

10.

Advances in the Diagnosis of Sepsis: Hydrogen Sulfide as a Prognostic Marker of Septic Shock Severity.

Košir M, Podbregar M.

EJIFCC. 2017 May 1;28(2):134-141. eCollection 2017 May.

11.

Outpatient beta-blockers and survival from sepsis: Results from a national cohort of Medicare beneficiaries.

Singer KE, Collins CE, Flahive JM, Wyman AS, Ayturk MD, Santry HP.

Am J Surg. 2017 Oct;214(4):577-582. doi: 10.1016/j.amjsurg.2017.06.007. Epub 2017 Jun 24.

PMID:
28666578
12.

Preadmission Use of Calcium Channel Blocking Agents Is Associated With Improved Outcomes in Patients With Sepsis: A Population-Based Propensity Score-Matched Cohort Study.

Lee CC, Lee MG, Lee WC, Lai CC, Chao CC, Hsu WH, Chang SS, Lee M.

Crit Care Med. 2017 Sep;45(9):1500-1508. doi: 10.1097/CCM.0000000000002550.

PMID:
28658023
13.

Survival, bacterial clearance and thrombocytopenia are improved in polymicrobial sepsis by targeting nuclear transport shuttles.

Veach RA, Liu Y, Zienkiewicz J, Wylezinski LS, Boyd KL, Wynn JL, Hawiger J.

PLoS One. 2017 Jun 19;12(6):e0179468. doi: 10.1371/journal.pone.0179468. eCollection 2017.

14.

CD155 blockade improves survival in experimental sepsis by reversing dendritic cell dysfunction.

Meng Y, Zhao Z, Zhu W, Yang T, Deng X, Bao R.

Biochem Biophys Res Commun. 2017 Aug 19;490(2):283-289. doi: 10.1016/j.bbrc.2017.06.037. Epub 2017 Jun 10.

PMID:
28610918
15.

Blockage of glycolysis by targeting PFKFB3 alleviates sepsis-related acute lung injury via suppressing inflammation and apoptosis of alveolar epithelial cells.

Gong Y, Lan H, Yu Z, Wang M, Wang S, Chen Y, Rao H, Li J, Sheng Z, Shao J.

Biochem Biophys Res Commun. 2017 Sep 16;491(2):522-529. doi: 10.1016/j.bbrc.2017.05.173. Epub 2017 May 30.

PMID:
28576491
16.

Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice.

Chen Y, Wang L, Kang Q, Zhang X, Yu G, Wan X, Wang J, Zhu K.

Cell Physiol Biochem. 2017;42(1):156-168. doi: 10.1159/000477308. Epub 2017 May 25.

17.

Aldosterone and Vascular Mineralocorticoid Receptors in Murine Endotoxic and Human Septic Shock.

Fadel F, André-Grégoire G, Gravez B, Bauvois B, Bouchet S, Sierra-Ramos C, Polito A, Mansart A, Alvarez de la Rosa D, Annane D, Jaisser F.

Crit Care Med. 2017 Sep;45(9):e954-e962. doi: 10.1097/CCM.0000000000002462.

PMID:
28445239
18.

Enhanced Glycolytic Metabolism Contributes to Cardiac Dysfunction in Polymicrobial Sepsis.

Zheng Z, Ma H, Zhang X, Tu F, Wang X, Ha T, Fan M, Liu L, Xu J, Yu K, Wang R, Kalbfleisch J, Kao R, Williams D, Li C.

J Infect Dis. 2017 May 1;215(9):1396-1406. doi: 10.1093/infdis/jix138.

PMID:
28368517
19.

Hepatic Induction of Fatty Acid Binding Protein 4 Plays a Pathogenic Role in Sepsis in Mice.

Hu B, Li Y, Gao L, Guo Y, Zhang Y, Chai X, Xu M, Yan J, Lu P, Ren S, Zeng S, Liu Y, Xie W, Huang M.

Am J Pathol. 2017 May;187(5):1059-1067. doi: 10.1016/j.ajpath.2017.01.002. Epub 2017 Mar 6.

PMID:
28279656
20.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators.

J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z.

Supplemental Content

Loading ...
Support Center